Organisation paid for research Program year 2025 Source: CMS Open Payments

Eresearch Technology, Incorporated

Neither a doctor nor a teaching hospital

Research payments

$1,295,095

14 payments

Through program year 2025, Eresearch Technology, Incorporated is reported as receiving $1,295,095 in research payments, across 14 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$784,351	4
2024	Research	$451,916	5
2023	Research	$31,795	3
2022	Research	$27,033	2

Breakdown

Who paid Research payments · program years 2022–2025

E.R. Squibb & Sons, L.L.C. $1,276,947 11 payments
Celgene Corporation $18,148 3 payments

Studies the money was for Research payments · program years 2022–2025

A Phase 1, Double-blind, Placebo-controlled, Randomized Study of the Safety, Tolerability, and Pharmacokinetics of BMS-986419 (Part 1) and a Phase 1 Randomized, Double-blind, Positive- controlled, Placebo-controlled, Parallel, Nested-crossover (moxifloxacin-placebo) Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants $481,464 1 payment
Relative BA / Pilot FE (NHV) - A Phase 1, Two-part, Open-label Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BMS-986365, Food and Proton Pump Inhibitor Effects, and Relative Bioavailability of BMS-986365 Capsule Com $282,397 1 payment
A Phase 1, Two-part, Open-label Single Ascending Dose Study to Evaluate Safety, Tolerability,and Pharmacokinetics of BMS-986365, Food and Proton Pump Inhibitor Effects, and RelativeBioavailability of BMS-986365 Capsule Compared to Tablet Formulation in Healthy Adult Male Participants $197,080 1 payment
A Phase 1, Open-label, Two-Part Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants $124,397 2 payments
A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants $77,227 1 payment
A Phase 1 Randomized, Doubleblind, Positivecontrolled, Placebocontrolled, 4Period Crossover, Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS986278 on Cardiac Repolarization in Healthy Participants $46,076 1 payment
Phase I J- MAD Study - A Phase 1 Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of MYK-224 in Healthy Adult Japanese Participants $37,670 2 payments
Phase I/II FIH Monotherapy/Combination $27,062 1 payment
Ph1 mCRPC (CC-90011-PCA-001) - A phase 1, open-label, functional imaging study to assess whether CC-90011 reverses the castration resistance due to lineage switch in participants with metastatic castration-resistant prostate cancer (mCRPC) who have failed $18,148 3 payments
SAD Cohorts - A Phase 1 Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single, Ascending Doses of BMS-986447 in Healthy Adult Participants $3,573 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.